FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200078862> ?p ?o ?g. }

• W3200078862 endingPage "4621" @default.
• W3200078862 startingPage "4621" @default.
• W3200078862 abstract "Data on the effectiveness and safety of approved SARS-CoV-2 vaccines in cancer patients are limited. This observational, prospective cohort study investigated the humoral immune response to SARS-CoV-2 vaccination in 232 cancer patients from 12 HeCOG-affiliated oncology departments compared to 100 healthcare volunteers without known active cancer. The seropositivity rate was measured 2–4 weeks after two vaccine doses, by evaluating neutralising antibodies against the SARS-CoV-2 spike protein using a commercially available immunoassay. Seropositivity was defined as ≥33.8 Binding-Antibody-Units (BAU)/mL. A total of 189 patients and 99 controls were eligible for this analysis. Among patients, 171 (90.5%) were seropositive after two vaccine doses, compared to 98% of controls (p = 0.015). Most seronegative patients were males (66.7%), >70-years-old (55.5%), with comorbidities (61.1%), and on active treatment (88.9%). The median antibody titers among patients were significantly lower than those of the controls (523 vs. 2050 BAU/mL; p < 0.001). The rate of protective titers was 54.5% in patients vs. 97% in controls (p < 0.001). Seropositivity rates and IgG titers in controls did not differ for any studied factor. In cancer patients, higher antibody titers were observed in never-smokers (p = 0.006), women (p = 0.022), <50-year-olds (p = 0.004), PS 0 (p = 0.029), and in breast or ovarian vs. other cancers. Adverse events were comparable to registration trials. In this cohort study, although the seropositivity rate after two vaccine doses in cancer patients seemed satisfactory, their antibody titers were significantly lower than in controls. Monitoring of responses and further elucidation of the clinical factors that affect immunity could guide adaptations of vaccine strategies for vulnerable subgroups." @default.
• W3200078862 created "2021-09-27" @default.
• W3200078862 creator A5001684767 @default.
• W3200078862 creator A5002813173 @default.
• W3200078862 creator A5011814780 @default.
• W3200078862 creator A5012832857 @default.
• W3200078862 creator A5015111096 @default.
• W3200078862 creator A5022772346 @default.
• W3200078862 creator A5024483658 @default.
• W3200078862 creator A5029532846 @default.
• W3200078862 creator A5030109945 @default.
• W3200078862 creator A5033733633 @default.
• W3200078862 creator A5041575636 @default.
• W3200078862 creator A5044610238 @default.
• W3200078862 creator A5059570367 @default.
• W3200078862 creator A5064636994 @default.
• W3200078862 creator A5080831980 @default.
• W3200078862 creator A5087117371 @default.
• W3200078862 creator A5088504271 @default.
• W3200078862 creator A5089796322 @default.
• W3200078862 creator A5090216312 @default.
• W3200078862 date "2021-09-15" @default.
• W3200078862 modified "2023-10-02" @default.
• W3200078862 title "Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group" @default.
• W3200078862 cites W1577251139 @default.
• W3200078862 cites W2000242801 @default.
• W3200078862 cites W2020073562 @default.
• W3200078862 cites W2052204012 @default.
• W3200078862 cites W2061001591 @default.
• W3200078862 cites W2096736686 @default.
• W3200078862 cites W2101114678 @default.
• W3200078862 cites W2109928588 @default.
• W3200078862 cites W2970378515 @default.
• W3200078862 cites W3023300354 @default.
• W3200078862 cites W3030573714 @default.
• W3200078862 cites W3032774217 @default.
• W3200078862 cites W3034965161 @default.
• W3200078862 cites W3043722389 @default.
• W3200078862 cites W3048259261 @default.
• W3200078862 cites W3082480386 @default.
• W3200078862 cites W3090844627 @default.
• W3200078862 cites W3091563171 @default.
• W3200078862 cites W3093729476 @default.
• W3200078862 cites W3094968263 @default.
• W3200078862 cites W3096689004 @default.
• W3200078862 cites W3097738396 @default.
• W3200078862 cites W3111255098 @default.
• W3200078862 cites W3111424223 @default.
• W3200078862 cites W3111590711 @default.
• W3200078862 cites W3117382778 @default.
• W3200078862 cites W3119688612 @default.
• W3200078862 cites W3125764896 @default.
• W3200078862 cites W3126623077 @default.
• W3200078862 cites W3127975759 @default.
• W3200078862 cites W3130161221 @default.
• W3200078862 cites W3132538114 @default.
• W3200078862 cites W3133958679 @default.
• W3200078862 cites W3135042813 @default.
• W3200078862 cites W3157453497 @default.
• W3200078862 cites W3158078097 @default.
• W3200078862 cites W3159628425 @default.
• W3200078862 cites W3159803579 @default.
• W3200078862 cites W3162131771 @default.
• W3200078862 cites W3164547793 @default.
• W3200078862 cites W3164768289 @default.
• W3200078862 cites W3165054140 @default.
• W3200078862 cites W3174178131 @default.
• W3200078862 cites W3175948812 @default.
• W3200078862 cites W3177279996 @default.
• W3200078862 cites W3182782630 @default.
• W3200078862 cites W3184765685 @default.
• W3200078862 cites W3193770227 @default.
• W3200078862 cites W4237483695 @default.
• W3200078862 doi "https://doi.org/10.3390/cancers13184621" @default.
• W3200078862 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8466969" @default.
• W3200078862 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34572848" @default.
• W3200078862 hasPublicationYear "2021" @default.
• W3200078862 type Work @default.
• W3200078862 sameAs 3200078862 @default.
• W3200078862 citedByCount "28" @default.
• W3200078862 countsByYear W32000788622021 @default.
• W3200078862 countsByYear W32000788622022 @default.
• W3200078862 countsByYear W32000788622023 @default.
• W3200078862 crossrefType "journal-article" @default.
• W3200078862 hasAuthorship W3200078862A5001684767 @default.
• W3200078862 hasAuthorship W3200078862A5002813173 @default.
• W3200078862 hasAuthorship W3200078862A5011814780 @default.
• W3200078862 hasAuthorship W3200078862A5012832857 @default.
• W3200078862 hasAuthorship W3200078862A5015111096 @default.
• W3200078862 hasAuthorship W3200078862A5022772346 @default.
• W3200078862 hasAuthorship W3200078862A5024483658 @default.
• W3200078862 hasAuthorship W3200078862A5029532846 @default.
• W3200078862 hasAuthorship W3200078862A5030109945 @default.
• W3200078862 hasAuthorship W3200078862A5033733633 @default.
• W3200078862 hasAuthorship W3200078862A5041575636 @default.
• W3200078862 hasAuthorship W3200078862A5044610238 @default.
• W3200078862 hasAuthorship W3200078862A5059570367 @default.
• W3200078862 hasAuthorship W3200078862A5064636994 @default.

• next